Search
forLearn
5 / 801 resultslearn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn HT-B
learn histidine
learn phenylanine
Research
5 / 328 resultsresearch Comparative Chemical Profiling and Monacolins Quantification in Red Yeast Rice Dietary Supplements by 1H-NMR and UHPLC-DAD-MS
Many red yeast rice supplements lack accurate monacolin labeling.
research 1H NMR-based lipidomics of rodent fur: species-specific lipid profiles and SCD1 inhibitor-related dermal toxicity
SCD1 inhibitors can cause skin issues in rodents.
research Synthesis of N-Substituted 3-Oxo-17b- carboxamide-4-aza-5a-androstanes and the Tautomerism of 3-Oxo-4-aza-5-androstenes
Researchers made two new compounds that could be used for medicine.
research Studies on synthesis of finasteride
The new method for making finasteride is cheaper and gives a higher yield.
research Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study
Certain metabolites are lower in women with PCOS and could be potential markers for the condition.
Community Join
5 / 1000+ resultscommunity EveryChem 3HP / PP30 page data vs NMR PDFs in their website : metadata mistake or document mismatch?
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.